Goldman Sachs
CUE icon

Goldman Sachs’s Cue Biopharma CUE Stock Holding History

Goldman Sachs’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,138
Closed -$7.85K – 6639
2026
Q1 		$7.85K Buy
1,138
+659
+138% +$6.15K ﹤0.01% 6390
2025
Q4 		$4.39K Sell
479
-1
-0.2% -$18 ﹤0.01% 6386
2025
Q3 		$10.3K Buy
480
+1
+0.2% +$23 ﹤0.01% 6257
2025
Q2 		$9.81K Sell
479
-1
-0.2% -$21 ﹤0.01% 6004
2025
Q1 		$13.1K Sell
480
-671
-58% -$24.9K ﹤0.01% 5961
2024
Q4 		$37.6K Buy
1,151
+532
+86% +$20K ﹤0.01% 5855
2024
Q3 		$14.1K Sell
619
-8,260
-93% -$179K ﹤0.01% 5689
2024
Q2 		$330K Buy
8,879
+7,358
+484% +$364K ﹤0.01% 5051
2024
Q1 		$86.3K Sell
1,521
-423
-22% -$29.8K ﹤0.01% 5265
2023
Q4 		$154K Buy
1,944
+1,307
+205% +$93.4K ﹤0.01% 5222
2023
Q3 		$44K Buy
637
+50
+9% +$4.88K ﹤0.01% 5289
2023
Q2 		$64.3K Buy
587
+123
+27% +$14.5K ﹤0.01% 5433
2023
Q1 		$49.7K Sell
464
-6
-1% -$572 ﹤0.01% 5554
2022
Q4 		$40.1K Buy
470
+4
+0.9% +$366 ﹤0.01% 5621
2022
Q3 		$31K Sell
466
-4,541
-91% -$391K ﹤0.01% 5855
2022
Q2 		$374K Sell
5,007
-12
-0.2% -$1.4K ﹤0.01% 5282
2022
Q1 		$735K Sell
5,019
-62
-1% -$13.1K ﹤0.01% 5068
2021
Q4 		$1.72M Sell
5,081
-2,733
-35% -$1.06M ﹤0.01% 4375
2021
Q3 		$3.42M Sell
7,814
-5,341
-41% -$1.86M ﹤0.01% 3697
2021
Q2 		$4.6M Sell
13,155
-6,915
-34% -$2.68M ﹤0.01% 3413
2021
Q1 		$7.35M Buy
20,070
+2,958
+17% +$1.22M ﹤0.01% 2814
2020
Q4 		$6.42M Buy
17,112
+5,854
+52% +$2.34M ﹤0.01% 2824
2020
Q3 		$5.08M Buy
11,258
+239
+2% +$138K ﹤0.01% 2884
2020
Q2 		$8.1M Buy
11,019
+5,805
+111% +$4.21M ﹤0.01% 2423
2020
Q1 		$2.22M Buy
+5,214
New +$2.53M ﹤0.01% 3226
2018
Q3 		– Sell
-413
Closed -$147K – 5588
2018
Q2 		$147K Buy
+413
New +$164K ﹤0.01% 5095

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM

Goldman Sachs's CUE Position: Q2 2026 in Review

Goldman Sachs sold out of Cue Biopharma (CUE) in Q2 2026, closing a stake of 1,138 shares — an estimated $7.85K sold.

Goldman Sachs first reported a position in CUE in Q2 2018 and held it in 26 quarters. The position peaked at $8.1M in Q2 2020. 49 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • Goldman Sachs reported no remaining Cue Biopharma position as of Q2 2026 after selling out during the quarter.
  • Goldman Sachs sold 1,138 Cue Biopharma shares in Q2 2026, an estimated $7.85K.
  • Goldman Sachs first reported a position in Cue Biopharma in Q2 2018 and held it in 26 quarters.
  • Goldman Sachs's Cue Biopharma position peaked at $8.1M in Q2 2020.
  • 49 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.